Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine

Hui Jan Tan, H. S. Teh, Raymond Azman Ali, Chee Yean Loo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: Migraine is a common disabling condition that results in considerable socioeconomic loss. The role of non-steroidal anti-inflammatory drugs (NSAIDs) in acute migraine has been well-established. We compared the efficacy of the cyclooxygenase-2 inhibitor celecoxib with the NSAID, naproxen sodium, in the treatment of acute migraine. Methods: This was a randomised, open label, controlled trial. We selected patients with a diagnosis of migraine, based on the International Headache Society revised criteria. 60 patients were randomised to either celecoxib 400 mg (30 patients) or naproxen sodium 550 mg (30 patients). Patients took the study medicine for the first acute migraine episode that occurred during the study period and reported the headache reduction based on a visual analogue score (VAS). Patients were reviewed after a month to check on VAS at one and two hours, compared to the baseline. Any side effects of the medication were also recorded. Results: Of the 52 patients who completed the study, eight did not experience any headaches. The mean VAS in the celecoxib group improved significantly from baseline (6.48 +/- 1.53) to one hour (4.28 +/- 2.11) and two hours (2.24 +/- 2.57) (p-value is less than 0.0005). The mean VAS in the naproxen sodium group also improved significantly from baseline (7.30 +/- 1.66) to one hour (4.81 +/- 2.50) and two hours (2.63 +/- 2.65) (p-value is less than 0.0005). However, there was no significant difference between the magnitudes of improvement between the treatment groups. The incidence of gastric pain was significantly higher in the naproxen sodium group (p-value is equal to 0.029). Conclusion: In comparison with naproxen sodium, celecoxib was equally effective in relieving pain in acute migraine and caused significantly less gastric pain.

Original languageEnglish
Pages (from-to)834-839
Number of pages6
JournalSingapore Medical Journal
Volume48
Issue number9
Publication statusPublished - Sep 2007

Fingerprint

Celecoxib
Migraine Disorders
Naproxen
Headache
Pain
Therapeutics
Stomach
Anti-Inflammatory Agents
Cyclooxygenase 2 Inhibitors
Pharmaceutical Preparations

Keywords

  • Acute migraine
  • Celecoxib
  • Drug side-effects
  • Gastric pain
  • Migraine
  • Naproxen sodium
  • Visual analogue score

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. / Tan, Hui Jan; Teh, H. S.; Ali, Raymond Azman; Loo, Chee Yean.

In: Singapore Medical Journal, Vol. 48, No. 9, 09.2007, p. 834-839.

Research output: Contribution to journalArticle

@article{8605fd9573c34b39bf1eea7ed569b1bd,
title = "Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine",
abstract = "Introduction: Migraine is a common disabling condition that results in considerable socioeconomic loss. The role of non-steroidal anti-inflammatory drugs (NSAIDs) in acute migraine has been well-established. We compared the efficacy of the cyclooxygenase-2 inhibitor celecoxib with the NSAID, naproxen sodium, in the treatment of acute migraine. Methods: This was a randomised, open label, controlled trial. We selected patients with a diagnosis of migraine, based on the International Headache Society revised criteria. 60 patients were randomised to either celecoxib 400 mg (30 patients) or naproxen sodium 550 mg (30 patients). Patients took the study medicine for the first acute migraine episode that occurred during the study period and reported the headache reduction based on a visual analogue score (VAS). Patients were reviewed after a month to check on VAS at one and two hours, compared to the baseline. Any side effects of the medication were also recorded. Results: Of the 52 patients who completed the study, eight did not experience any headaches. The mean VAS in the celecoxib group improved significantly from baseline (6.48 +/- 1.53) to one hour (4.28 +/- 2.11) and two hours (2.24 +/- 2.57) (p-value is less than 0.0005). The mean VAS in the naproxen sodium group also improved significantly from baseline (7.30 +/- 1.66) to one hour (4.81 +/- 2.50) and two hours (2.63 +/- 2.65) (p-value is less than 0.0005). However, there was no significant difference between the magnitudes of improvement between the treatment groups. The incidence of gastric pain was significantly higher in the naproxen sodium group (p-value is equal to 0.029). Conclusion: In comparison with naproxen sodium, celecoxib was equally effective in relieving pain in acute migraine and caused significantly less gastric pain.",
keywords = "Acute migraine, Celecoxib, Drug side-effects, Gastric pain, Migraine, Naproxen sodium, Visual analogue score",
author = "Tan, {Hui Jan} and Teh, {H. S.} and Ali, {Raymond Azman} and Loo, {Chee Yean}",
year = "2007",
month = "9",
language = "English",
volume = "48",
pages = "834--839",
journal = "Singapore Medical Journal",
issn = "0037-5675",
publisher = "Singapore Medical Association",
number = "9",

}

TY - JOUR

T1 - Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine

AU - Tan, Hui Jan

AU - Teh, H. S.

AU - Ali, Raymond Azman

AU - Loo, Chee Yean

PY - 2007/9

Y1 - 2007/9

N2 - Introduction: Migraine is a common disabling condition that results in considerable socioeconomic loss. The role of non-steroidal anti-inflammatory drugs (NSAIDs) in acute migraine has been well-established. We compared the efficacy of the cyclooxygenase-2 inhibitor celecoxib with the NSAID, naproxen sodium, in the treatment of acute migraine. Methods: This was a randomised, open label, controlled trial. We selected patients with a diagnosis of migraine, based on the International Headache Society revised criteria. 60 patients were randomised to either celecoxib 400 mg (30 patients) or naproxen sodium 550 mg (30 patients). Patients took the study medicine for the first acute migraine episode that occurred during the study period and reported the headache reduction based on a visual analogue score (VAS). Patients were reviewed after a month to check on VAS at one and two hours, compared to the baseline. Any side effects of the medication were also recorded. Results: Of the 52 patients who completed the study, eight did not experience any headaches. The mean VAS in the celecoxib group improved significantly from baseline (6.48 +/- 1.53) to one hour (4.28 +/- 2.11) and two hours (2.24 +/- 2.57) (p-value is less than 0.0005). The mean VAS in the naproxen sodium group also improved significantly from baseline (7.30 +/- 1.66) to one hour (4.81 +/- 2.50) and two hours (2.63 +/- 2.65) (p-value is less than 0.0005). However, there was no significant difference between the magnitudes of improvement between the treatment groups. The incidence of gastric pain was significantly higher in the naproxen sodium group (p-value is equal to 0.029). Conclusion: In comparison with naproxen sodium, celecoxib was equally effective in relieving pain in acute migraine and caused significantly less gastric pain.

AB - Introduction: Migraine is a common disabling condition that results in considerable socioeconomic loss. The role of non-steroidal anti-inflammatory drugs (NSAIDs) in acute migraine has been well-established. We compared the efficacy of the cyclooxygenase-2 inhibitor celecoxib with the NSAID, naproxen sodium, in the treatment of acute migraine. Methods: This was a randomised, open label, controlled trial. We selected patients with a diagnosis of migraine, based on the International Headache Society revised criteria. 60 patients were randomised to either celecoxib 400 mg (30 patients) or naproxen sodium 550 mg (30 patients). Patients took the study medicine for the first acute migraine episode that occurred during the study period and reported the headache reduction based on a visual analogue score (VAS). Patients were reviewed after a month to check on VAS at one and two hours, compared to the baseline. Any side effects of the medication were also recorded. Results: Of the 52 patients who completed the study, eight did not experience any headaches. The mean VAS in the celecoxib group improved significantly from baseline (6.48 +/- 1.53) to one hour (4.28 +/- 2.11) and two hours (2.24 +/- 2.57) (p-value is less than 0.0005). The mean VAS in the naproxen sodium group also improved significantly from baseline (7.30 +/- 1.66) to one hour (4.81 +/- 2.50) and two hours (2.63 +/- 2.65) (p-value is less than 0.0005). However, there was no significant difference between the magnitudes of improvement between the treatment groups. The incidence of gastric pain was significantly higher in the naproxen sodium group (p-value is equal to 0.029). Conclusion: In comparison with naproxen sodium, celecoxib was equally effective in relieving pain in acute migraine and caused significantly less gastric pain.

KW - Acute migraine

KW - Celecoxib

KW - Drug side-effects

KW - Gastric pain

KW - Migraine

KW - Naproxen sodium

KW - Visual analogue score

UR - http://www.scopus.com/inward/record.url?scp=35848948631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848948631&partnerID=8YFLogxK

M3 - Article

C2 - 17728965

AN - SCOPUS:35848948631

VL - 48

SP - 834

EP - 839

JO - Singapore Medical Journal

JF - Singapore Medical Journal

SN - 0037-5675

IS - 9

ER -